Aim: A risk-adapted strategy for metastatic seminoma may further refine the necessary burden of chemotherapy while sparing futile treatment for early recognized good responders. The objective of this proof-of-principle study was to evaluate the association of an early metabolic response to PEB and the dimensional response at the end of treatment. Methods: Patients ( pts) with newly-diagnosed seminoma and who were candidate to PEB were staged at baseline by computed tomography (CT), PET and serum tumor markers (STM). Then, restaging with PET after 2 cycles of PEB (PET 2 ), and with CT after treatment (3-4 cycles [CT 3-4 ]) were provided. One (greatest) target lesion was chosen to evaluate metabolic/dimensional changes in each case. The primary endpoint was the association between PET 2 (EORTC criteria) and CT 3-4 response. Secondary endpoints were progression-free survival (PFS) and ability to detect visceral metastases. An analysis after the initial 35 pts was planned. Results: In the time-frame 06
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